Clinical PerformanceThe DurAVR system has shown premier acute and long-term hemodynamic outcomes in first-in-human and early feasibility studies, signaling potential success in upcoming pivotal studies.
Product DevelopmentAnteris has developed DurAVR, a first-in-class biomimetic TAVR platform with disruptive potential.
Regulatory ProgressAnteris released its Q4 results, highlighting significant progress toward securing FDA approval for the DurAVR TAVR system.